Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22/CD19 CAR-T for High-Risk B-cell Lymphoma Consolidation
NCT07094477Phase 2Active, not recruiting
- Sponsor
- Daihong Liu
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of cd22 car-t + cd19 car-t in B cell lymphoma, sponsored by Daihong Liu. Started Apr 2025; status: active, not recruiting.
02
Drugs
cd22 car-t + cd19 car-t
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07094477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094477.